TNF and ulcerative colitis: A recent registry-based Spanish study reported a trend for higher 1-year response and remission rates with adalimumab therapy in anti-TNFα-naïve patients with ulcerative colitis compared with those previously treated with an anti-TNFα agent in routine clinical practice [25].